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ABSTRACT
Aims To assess the cost-effectiveness of alternative smoking cessation scenarios from the perspective of the Spanish
National Health Service (NHS). Design We used the European study on Quantifying Utility of Investment in Protection
from Tobacco model (EQUIPTMOD), a Markov-based state transition economic model, to estimate the return on
investment (ROI) of: (a) the current provision of smoking cessation services (brief physician advice and printed
self-helped material + smoking ban and tobacco duty at current levels); and (b) four alternative scenarios to complement
the current provision: coverage of proactive telephone calls; nicotine replacement therapy (mono and combo) [prescription
nicotine replacement therapy (Rx NRT)]; varenicline (standard duration); or bupropion. A rate of 3% was used to
discount life-time costs and benefits. Setting Spain. Participants Adult smoking population (16+ years).
Measurements Health-care costs associated with treatment of smoking attributable diseases (lung cancer, coronary
heart disease, chronic obstructive pulmonary infection and stroke); intervention costs; quality-adjusted life years (QALYs).
Costs and outcomes were summarized using various ROI estimates. Findings The cost of implementing the current
provision of smoking cessation services is approximately €61 million in the current year. This translates to 18 quitters
per 1000 smokers and a life-time benefit–cost ratio of 5, compared with no such provision. All alternative scenarios were
dominant (cost-saving: less expensive to run and generatedmore QALYs) from the life-time perspective, compared with the
current provision. The life-time benefit–cost ratios were: 1.87 (proactive telephone calls); 1.17 (Rx NRT); 2.40
(varenicline-standard duration); and bupropion (2.18). The results remained robust in the sensitivity analysis.
Conclusions According to the EQUIPTMODmodelling tool it would be cost-effective for the Spanish authorities to expand
the reach of existing GP brief interventions for smoking cessation, provide pro-active telephone support, and reimburse
smoking cessationmedication to smokers trying to stop. Such policies would more than pay for themselves in the long run.
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INTRODUCTION
Smoking is the leading cause of preventable death [1],
causing nearly 6 million deaths per year globally. Of those,
more than 5 million are the result of direct tobacco use
while more than 600000 are the result of non-smokers
being exposed to second-hand smoke world-wide [2].
Although the European Union (EU) has made many
efforts in reducing the tobacco problem, the number of
smokers during the last decade is still high: 28% of the
EU population smokes [3]. The smoking prevalence in
Spain is 27%, despite a significant drop (by five percent-
age points) observed since 2006 [4]. Therefore, smoking
is still a major cause of health and social care costs
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faced by Spanish society [5–10]. In the Law 28/2005,
the Spanish Council of State highlight that state expen-
diture to cover the health and social care costs caused
by smoking exceed the excise duty levied on tobacco
products [11].
Top-level actions for reducing the prevalence of
smoking in Spain have been a priority, e.g. the Law
42/2010. Indoor smoking bans, tobacco duties (taxation)
and regulation of tobacco advertising have been found to
be effective in increasing quit attempts [12]. In the Spanish
Health Survey 2011–12, the percentage of smokers who
tried to quit during 1 year decreased from 24 to 19%. A
large proportion (80%) of smokers reported not using any
medication or advice/support from a doctor or trained pro-
fessionals [13]. In Spain, there are four main behavioural
interventions that could be implemented at a national
level: specialist support (one-to-one or group-based); tele-
phone support; or short message service (SMS) text mes-
saging. Moreover, three main pharmacological options
could be implemented: nicotine replacement therapy
(NRT) in various forms (gum or patch), bupropion and
varenicline. These interventions are cost-effective strate-
gies [14–16] but are not covered currently by the Spanish
National Health Service (NHS) or the coverage is limited to
certain groups (health-care workers or people with limited
resources). According to the World Health Organization
[17], Spain has national smoke-free legislation; a tobacco
taxation policy; complete bans on tobacco advertising,
promotion and sponsorship; services to treat tobacco
dependence; and requirements to put health warnings on
tobacco packages. However, Spanish decision-makers cur-
rently lack information on the costs and potential benefits
of investing in the new smoking cessation interventions
or improving the reach of existing services. A rigorous
analysis of alternative investment strategies is therefore
needed.
When making funding decisions, health-care adminis-
trators need evidence on efficacy and costs of deploying in-
dividual tobacco control measures in order to justify their
investment. The ‘expert consensus document on tobacco
addiction treatment in Spain’, supported by the Ministry
of Health and Consumer Affairs of Spain, published in
2009, pointed out that the final definition of a common
minimum care strategy in the country should be based
on criteria of cost-effectiveness. Currently, smoke-free poli-
cies and tobacco duty are in place encouraging smokers
to make a quit attempt [12,17]. Other interventions target
smokers who are motivated to quit, and include printed
self-helpmaterials and brief physician advice, although this
is funded only in some regions of Spain. At the regional
level, offering general practitioner (GP) brief physician ad-
vice in Spain is cost-effective [€7260 per quality-adjusted
life years (QALYs) gained] [18]. However, pharmacother-
apy [such as nicotine replacement therapy (NRT),
varenicline or bupropion] is not currently covered by the
Spanish NHS [19,20].
The aim of this study is therefore to estimate the cost-
effectiveness of alternative smoking cessation scenarios.
We assessed the following scenarios: (a) the current provi-
sion of smoking cessation services (brief physician advice
and printed self-help material as well as an indoor smoking
ban and a smoking duty at current levels); and four
alternative scenarios: coverage of proactive telephone
calls; nicotine replacement therapy (mono and combo)
[prescription (Rx) NRT]; varenicline (standard duration);
or bupropion, to complement the current provision.
METHODS
Model description
We used the European study on Quantifying Utility of
Investment in Protection from Tobacco model
(EQUIPTMOD), a Markov-based state transition model, to
estimate the return on investment (ROI) of alternative
smoking cessation scenarios. The EQUIPTMOD is described
in detail elsewhere [21], but a top-level summary of the
model workings is provided here. This is a cohort model
with three states: current smoker, former smokers and
death. Individuals (16+ years) in the cohort can either stay
within their current state or move to one of the other two
states except for death, which is an absorbing state. A
yearly cycle was chosen because it allowed the model to
consider the natural progression and resolution of the
disease. In each cycle, smokers and former smokers from
the cohort model have the chance of having four condi-
tions: lung cancer (LC); coronary heart disease (CHD);
chronic obstructive pulmonary disease (COPD); and stroke
(ST). Population-weighted costs and QALYs are calculated
for each age- and sex-specific group during the life-time
(until 100 years of age) and then converted to various
ROI estimates. Both health-care cost-savings and the value
of willingness-to-pay for a QALY gain (otherwise, known as
the cost-effectiveness threshold) are used to estimate
benefit–cost ratios.
The main model outputs used in this analysis in-
clude: economic impact (loss productivity and passive
smoking costs), health-care costs savings, QALYs, the
incremental cost-effectiveness ratio (ICER); and benefit–
cost ratio. ICERs measure extra costs needed to imple-
ment a scenario per QALY gain in relation to the
comparator. Benefit–cost ratios measure the return
(in €) on every €1 invested in the scenario, and may in-
clude only health-care savings or also the value of the
QALY gains to calculate the benefits. All ROI estimates
were calculated from the perspective of the Spanish
NHS. Where possible, a quasi-societal perspective
(to include productivity gains) was also considered.
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Model inputs
Several sources of evidence were used to inform the model
with regard to the Spanish context. Respective literature
reviews were carried out between 2014 and 2016 and,
where necessary, international databases were used to
acquire data for the model inputs. The input data were:
general population data (such as population distribution,
age- and sex-specific mortality rates, smoking prevalence
and relative risks); disease prevalence; motivation to quit;
intervention reach (varenicline; bupropion; telephone
support; printed self-help materials; brief physician advice;
taxation increase; and indoor smoking ban); intervention
effectiveness (varenicline; bupropion; telephone support;
and printed self-help material); disease costs; intervention
costs (varenicline; bupropion telephone support; and
printed self-help material); costs attributable to passive
smoking in children and adults; utilities (never smokers;
current and former smoker; LC, CHD; COPD; ST); and pro-
ductivity losses (work-days lost per smoker; average hourly
wage; and employment among smokers). After examina-
tion of literature reviews, diseases attributable to passive
smoking in children included acute otitis media (AOM),
lower respiratory tract (LRT) infections; and asthma. How-
ever, in adults, passive smoking-related conditions included
LC, CHD and asthma [21]. The rate used to discount future
costs and QALYs was 3%, following Spanish guidelines on
health technologies assessment and economic evaluations
[22]. We used the cost-effectiveness interval threshold
values per QALY gain in Spain (€21000–24000) as
derived from a recent estimation [23].The threshold value
is the societal willingness-to-pay for a QALY gain and is
used widely in cost-effectiveness analysis. This value was
also used to translate QALY gains into monetary benefits
to derive the benefit–cost ratios. Themean unit and annual
costs were converted to € (2015) using country-specific in-
terannual inflation rate from the price year to 2015 [24].
Table 1 shows details of the data required to populate
the model.
Interventions and investment scenarios
We considered the following investment scenarios.
Current provision of services
Brief physician advice and printed self-help material were
available at the current levels of reach. Although there
has been no clear stated public strategy in the country
for brief physician advice as part of public funding, the Na-
tional Committee for Smoking Prevention (CNPT) jointly
with theMinistry of Health and Consumer Affairs identified
and recommended brief physician advice as an essential
intervention to promote smoking cessation [12,19,20]. In
addition, provision of health-care services is decentralized
in several autonomous communities. Some of these regions
are currently funding the brief physician advice interven-
tions and a few others are not. Therefore, in order to estab-
lish the definition of the current provision of cessation
services it was decided to include brief physician advice as
if this was funded by all regions. As Spain already has a
smoking ban and tobacco duty, the current provision was
also assumed to have these two top-level interventions as
they exist currently. The current provision (brief physician
advice + printed self-help materials + smoking ban + to-
bacco duty at the current levels) was thus compared with
the ‘baseline’ (existing smoking ban + tobacco duty at
the current levels).
Alternative scenarios
Alternative scenarios included proactive telephone calls;
prescription nicotine replacement therapy (Rx NRT: mono
and combo); varenicline; or bupropion; used separately
to complement the current provision. Spanish experts
have recommended proactive telephone calls and
cessation medications for national implementation from
efficacy/effectiveness perspectives, but not considering
cost-effectiveness [12]. This analysis will address this lack
of information on the cost-effectiveness of those interven-
tions if they were to be implemented to complement the
current provision of services.
Details on intervention reach, relative effectiveness and
cost of intervention are provided in Table 2.
Sensitivity analysis
We analysed the uncertainty around model inputs. Deter-
ministic univariate sensitivity analysis was conducted by
changing the discount rate from 0 to 5%. Probabilistic
sensitivity analysis (PSA)was undertaken by sampling ran-
domly from the distribution of each of the input value and
calculating the expected costs and expected QALYs for that
combination of input values. Details on distributions and
parameters uncertainty are provided elsewhere [21]. One
thousand Monte Carlo simulations were conducted from
these distributions [25]. Transition probabilities were char-
acterized by beta distributions; relative risks and odds ratios
by log-normal distributions; utility values specific to
smoking status by beta distributions; utility decrements as-
sociated with smoking-related disease by normal distribu-
tions; and costs by gamma distributions, although
intervention costs were assumed to be fixed, as were
population-level data. When no uncertainty boundaries
were obtained for the included input estimates in the
model, analysis then adopts standard methods for defining
uncertainty concerning input values [25]. The PSA was
conducted to compare the alternative scenarios with the
baseline, as allowed by the EQUIPTMOD.
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RESULTS
The results (model outputs) described in this section and in
Table 3 refer to the Spanish adult (16+ years) population of
approximately 39.2 million, of whom approximately
10.5 million (26.9%) are smokers and 7.7 million
(19.6%) are former smokers. Of all current smokers
throughout Spain, approximately 3.1 million (30%) would
make a quit attempt in the next 12months. Approximately
€61 million would be required to spend on services to
deliver the current provision (brief physician advice
and self-help material on top of smoking ban and
tobacco duty at current levels) nationally in Spain
(currently, this happens in only some regions). This
investment would lead to 193128 successful quitters,
i.e. 18 per 1000 smokers. Every £1 invested in the cur-
rent provision nationally has the potential to generate
£5 during the life-time compared to the baseline
Table 1 Inputs to populate the model for the Spanish context.
Inputs Input value (mean) Standard error or 95% CI Source
General data
Population Age– and sex–dependent – [26]
Mortality rates Age- and sex-dependent – [27]
Smoking prevalence Age- and sex-dependent – [4]
Relative risks Age-dependent – [28,29]
Disease prevalence
Lung cancer Age- and sex-dependent – [30,31]
CHD Age- and sex-dependent – [32]
COPD Age- and sex-dependent – [33]
ST Age- and sex-dependent – [9,34]
Motivation to quit 36.49% SE (0.0080961); CI 95%
(0.3490–0.3807)
[4]
Costs (all expressed in €2015)
Disease costs –
Lung cancer costs 15289.86 – [35]
CHD costs 1 454.37 – [36,37]
COPD costs 4123.75 – [38]
ST costs 8424.39 – [39,40]
Passive smoking
Cost attributable to passive smoking in children (annual cost per case)
AOM 2538 – [41]
LRT infections 3324 – [41]
Asthma 775 – [42]
Cost attributable to passive smoking in adults (annual cost per case)
Lung cancer 15290 – [35]
CHD 1454 – [36,37]
Asthma 1533 – [43]
Utilities
Never smokers (include all the smoking-
attributable diseases)
0.884 – [44]
Current smokers (include all the smoking
attributable diseases)
0.85 – [44]
Former smokers (include all the smoking
attributable diseases)
0.869 – [44]
LC 0.56 – [45]
CHD 0.621 – [45]
COPD 0.732 – [45]
ST 0.550 – [45]
Productivity loses
Work-days lost per smoker 6 days – [46]
Average hourly wage 15.93 (men); 13.18 (women) – [47]
Employment among smokers 53.52% (employed); 22.53% (unemployed);
10.86% (retired); 13.08% (others)
– [4]
CHD = coronary heart disease; COPD= chronic obstructive pulmonary disease; ST = stroke; CI = confidence interval; SE = standard error; AOM= acute otitis
media; LRT = lower respiratory tract.
68 Marta Trapero-Bertran et al.
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 113 (Suppl. 1), 65–75
scenario, where no brief advice and printed materials
were available (Table 3).
Implementing proactive telephone calls to complement
the current provision would require an additional invest-
ment of approximately €12.6 million. However, this would
generate 1053 additional successful quitters. For every €1
spent on providing this intervention to smokers who are
trying to stop smoking, the NHS could recoup €1.87 in
health-care cost savings during the long term (Table 3).
Providing cessation medications to complement the
current provision would generate additional quitters. In-
cluding Tx NRT (mono and combo), for example, would
generate 6905 additional quitters at an additional invest-
ment of approximately €260 million. For every €1 spent
on providing this intervention, the NHS could recoup
€1.17 in health-care cost savings during the long term
(Table 3). The corresponding figure for other alternative
scenarios was, respectively, €2.40 (varenicline) and
€2.18 (bupropion).
Table 3 also shows that all scenarios were ‘dominant’
(i.e. cost-saving: less expensive to run but generates more
QALYs than the comparator) on the life-time horizon.
ICERs calculated for the 10-year horizon shows that all
scenarios are cost-effective, as the incremental costs for a
QALY gain (e.g. €7968 for proactive calls) are well below
or within the Spanish cost-effectiveness interval threshold
of €21000–24000 for all scenarios.
The effect of scenarios on productivity gains and reduc-
tion of passive smoking costs was small at per-smoker level
(Table 3). However, when translated to the population
level, these effects can deliver notable cost-savings. For ex-
ample, if only 2% of the 10.5million smokers were reached
via proactive telephone calls, we would gain €84000 in
productivity and €29400 in the treatment of passive
smoking-related diseases in children.
On deterministic sensitivity analysis, the scenario in-
volving proactive telephone calls was cost-effective com-
pared to the current provision for a 3% discount rate
after 10 years, but for a 0% discount rate it was cost-
effective after 5 years. For alternative scenarios involving
varenicline and bupropion, decisions based on life-time
cost-effectiveness remained the same regardless of the dis-
count rate used. The results from the PSA are shown in
Figure 1, where incremental costs and incremental QALYs
are plotted. As seen in the figure, most of the dots fell into
the cost-saving quadrant. The cost-effectiveness acceptabil-
ity curve (CEAC) is presented in Figure 2. At the Spanish in-
terval threshold value from €21000 to 24000 per QALY,
Table 2 Data on reach, relative effectiveness and costs of interventions.
Interventions Reach (source)
Relative effectiveness
(SD) (source)
Cost per smoker
(€ 2015) (source)
Current provision
Top-level interventions
Brief physician advice 21% of smokers not previously prepared to
make a quit attempt receive brief physician
advice [48]
1.40 (0.3910) [49] 26.67 [50]
Tobacco duty All (100%) smokers are exposed to tobacco
duty [48]
1.20 (0.1637) [51] 0
Indoor smoking ban All (100%) smokers are exposed to indoor
smoking ban [48]
1.10 (0.1562) [52] 0
Pharmacological interventions – – –
Behavioural interventions
Printed self-help materials 1% of smokers who make quit attempts
receive self-help materials [48]
1.19 (0.2701) [53] 17.62 [54]
Alternative scenario with proactive telephone support (current provision + telephone support)
Behavioural interventions
Telephone support (proactive) 0.5% of smokers who make quit attempts
make use of the telephone support [48]
1.40 (0.1709) [55] 205.04 [56]
Alternative scenario with medications (current provision + varenicline/bupropion/Rx NRT)
Varenicline (standard duration) 5% of smokers motivated to quit use
varenicline (standard duration) [48]
2.30 (0.2283) [57] 298.33 [19,58,59]
Bupropion 1% of smokers motivated to quit use
bupropion [48]
1.60 (0.2267) [60] 151.28 [19,58,59]
Rx mono NRT 5% of smokers motivated to quit use
OTC mono NRT [48]
1.60 (0.0917) [61] 276.38 [19,58,59]
Rx combo NRT 2% of smokers motivated to quit use
OTC combo NRT [48]
2.14 (0.2417) [61] 554.19 [19,58,59]
SD = standard deviation; NRT = nicotine replacement therapy; OTC = over-the-counter.
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the probability that the current provision is cost-effective
compared to the baseline is approximately 96%.
DISCUSSION
Decision analytical models are necessary to inform
decision-making by bringing together existing evidence to
assess the probable cost-effectiveness of competing forms
of smoking cessation programmes. This study is the first
to evaluate the cost-effectiveness of the current and poten-
tial investment scenarios on smoking cessation in Spain.
The analysis based on the EQUIPTMOD, presented in this
paper, incorporated the full range of assumptions used to
assess cost-effectiveness during the life-time in the Spanish
population. This study has demonstrated a practical appli-
cation of the EQUIPT ROI tool in Spain to evaluate both the
existing and several potential investment scenarios to
improve smoking cessation [62]. Our findings show that
the current provision is cost-saving, showing that tobacco
control in Spain appears to move in the right direction.
However, we evaluated the current provision on the as-
sumption that brief physician advice would be extended
and implemented in all Spanish regions, which is not the
case currently [19,20]. This implies that a definitive action
needs to be taken by the Government in order to increase
the reach of this intervention to cover the whole country.
Our findings also point to a new direction of travel for
Spanish decision-makers. The alternative scenario with
proactive telephone calls implied an extra investment of
€10.8 million to generate 1053 successful quitters. For
each one extra successful quitter, the Government will
therefore have to pay €10253. After 10 years, this inter-
vention would be cost-saving. If the Government is willing
to pay an extra €15.9 million, instead of €10.8 million, to
implement a national strategy with bupropion, this would
generate an extra 1811 successful quitters. In this case,
gaining one extra successful quitter will cost the Govern-
ment €8797, allowing the Government to save €1455
Figure 2 Cost-effectiveness acceptability curve
(current provision versus the baseline)
Figure 1 Cost-effectiveness plane plotting in-
cremental costs and incremental quality-adjusted
life years (QALYs) (current provision versus the
baseline)
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per successful quitter. However, from the viewpoint of
cost-effectiveness alone, bupropion is not the most efficient
intervention; varenicline (standard duration) is the most
efficient. Implementing the varenicline scenario would
require an extra investment of almost €157 million, which
is a much larger investment than the extra €15.9 million
needed to fund bupropion. Our analysis thus provides
decision-makers with alternative policy options with a
potential budgetary impact.
The model presented some limitations that need to be
considered in order to interpret the results. First, the model
did not include possible adverse events of any of the medi-
cations considered. Conversely, for some particular diseases
the model did not include any potential protective effects of
smoking. It is fair to assume a trivial impact of this on our
conclusions, given the scale of estimated health-care sav-
ings and QALY gains in our analysis. Secondly, due to the
lack of data on smoking status-specific relative risks, it
was not possible to ‘split’ former smokers into ‘recent’
and ‘long-term’ categories. It is reasonable to assume that
the use of a large sample size (7.7 million former smokers)
included in the analysis might have mitigated the impact of
this, although to what extent remains unclear. Thirdly,
within themodel it is assumed that smokers only try to stop
smoking once within the first year. In subsequent years,
the background quit rate was assumed to reflect the bal-
ance of quitting and relapsing. In real life, smokers who fail
to quit smoking with one intervention may be more likely
to repeat the same intervention or try a number of different
interventions [63]. Furthermore, smokers who do not stop
may do so in later years, thus partly lowering the incre-
mental effect of cessation. Fourthly, no country-specific ef-
fectiveness data could be retrieved for the evaluated
interventions in Spain. However, Cochrane effectiveness in-
puts used in this model represent rigorous evidence from a
wide range of studies world-wide and are well accepted in
the research community. Fifthly, interactions between
pharmaceuticals and behavioural interventions were in-
cluded within themodel using amultiplicative assumption,
as specific data regarding the combinations were not avail-
able in the literature. Finally, an important limitation of
EQUIPTMODwas the restriction posed by its PSA function-
ality. The economic model was developed primarily to un-
derpin a ROI tool for decision-making purposes. This
objective inevitably required the tool developers to not only
provide a simple generalized user interface (GUI) and gran-
ularity of outputs (a number of ROI metrics) but, signifi-
cantly, also subjected them to consider Microsoft Excel’s
own limitations to handle such a large model. The PSA
functionality available to the users was therefore restricted
to providing sensitivity estimates for the current provision
compared to the baseline. Future research will benefit
from further development on the PSA functionality of the
EQUIPTMOD.
Treatment costs used in the model only took into
account the hospitalization costs, because such costs in
Spain are available only at hospital level. Therefore, there
is a need to calculate health-care costs attributable to
smoking-related diseases by including not only hospital-
related costs, but also the downstream costs relevant to
the entire disease episode.
CONCLUSION
Analysis based on the EQUIPTMOD has provided Spanish
decision-makers with policy options for tobacco control. It
would be cost-effective to expand the reach of GP brief
interventions to all areas of Spain, provide proactive
telephone support and reimburse smoking cessation
medication to smokers trying to stop. During a life-time,
these policies would be cost-saving.
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